<< Read Full Article
<< Read Full Article
Biotech and pharmaceutical companies put the brakes on a few clinical trials but also announced positive recommendations for European regulatory approvals Friday.
First, biotechnology company Maxygen(MAXY) announced that Roche put on hold clinical development of MAXY-alpha, a treatment for hepatitis C and hepatitis B virus infections.
Maxygen, which licenses the drug to Roche, said that in the phase I trial, it observed a reduction of efficacy in the majority of patients who received two doses of MAXY-alpha. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,741.98 | 1,159.90 | 2,374.41 | 36.87 |
Oil *
79.80
|
|
DOWN
37.19
|
DOWN
5.92
|
DOWN
16.87
|
UP
0.15
|
10 Yr
3.69%
SPDR Gold
108.28
|
|
-0.34%
|
-0.51%
|
-0.71%
|
+0.41%
|
Data delayed 20 minutes |
More From TheStreet
Latest Headlines
Brokerage Partners
Sponsored Links
Connect with TheStreet